SHY is a private, U.S. biotechnology company developing small molecule therapeutics that non-covalently target ATPases and GTPases and modulate their activity. ATPases and GTPases are proteins central to the development of many serious diseases. SHY’s unique molecule portfolio enables us to target ATPases and GTPases associated with serious unmet medical needs, yet often considered undruggable, and to identify and address new treatment targets. SHY will file its first IND in the second half of 2025 for a novel first-in-class cancer therapeutic candidate targeting the proteasome 19S regulatory subunit.
Company Details
- Employees
- 11
- Founded
- -
- Address
- New York City, Ny, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Biotech, Proteasome, Small Molecules, Oncology.
- HQ
- New York City, NY
Shy Therapeutics Questions
Shy Therapeutics's LinkedIn profile is https://www.linkedin.com/company/shy-therapeutics-llc
Shy Therapeutics has
11 employees.
View email and phone details for 11
employees at Shy Therapeutics.
Shy Therapeutics's industry is
Biotechnology Research
Shy Therapeutics's top competitors are
Shy Therapeutics,
Applied Materials,
Genomic Observatory Inc,
Jade Biosciences,
Bioct,
Spotlight Safety Inc.,
Oligomerix, Inc,
Bristol Myers Squibb,
Jasper Therapeutics,
Red Queen Therapeutics.
Shy Therapeutics's categories are Biotechnology Research
Shy Therapeutics's founding year is 2015
